Atm loss does not radiosensitize a primary mouse model of Pten-deleted brainstem glioma

Diffuse midline gliomas arise in the brainstem and other midline brain structures and cause a large proportion of childhood brain tumor deaths. Radiation therapy is the most effective treatment option, but these tumors ultimately progress. Inhibition of the phosphoinositide-3-kinase (PI3K)-like kinase ataxia telangiectasia mutated (ATM), which orchestrates the cellular response to radiation-induced DNA damage, may enhance the efficacy of radiation therapy. Diffuse midline gliomas in the brainstem contain loss-of-function mutations in the tumor suppressor PTEN, or functionally similar alterations in the phosphoinositide-3-kinase (PI3K) pathway, at moderate frequency. Here, we sought to determine if Atm inactivation could radiosensitize a primary mouse model of brainstem glioma driven by Pten loss. Using Cre/loxP recombinase technology and the RCAS/TVA retroviral gene delivery system, we established a mouse model of brainstem glioma driven by Pten deletion. We find that Pten-null brainstem gliomas are relatively radiosensitive at baseline. In addition, we show that deletion of Atm in the tumor cells does not extend survival of mice bearing Pten-null brainstem gliomas after focal brain irradiation. These results characterize a novel primary mouse model of PTEN-mutated brainstem glioma and provide insights into the mechanism of radiosensitization by Atm deletion, which may guide the design of future clinical trials. Brief Summary We develop a mouse model of PTEN-mutated brainstem glioma and find that perturbation of the ATM does not enhance radiation efficacy in this model.

[1]  R. Beroukhim,et al.  PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation , 2022, Nature communications.

[2]  D. Kirsch,et al.  Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiotherapy. , 2021, International journal of radiation oncology, biology, physics.

[3]  D. Kirsch,et al.  Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models. , 2020, The Journal of clinical investigation.

[4]  M. Monje,et al.  ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma , 2019, Communications Biology.

[5]  R. McLendon,et al.  ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis , 2019, Nature Communications.

[6]  I. Barrett,et al.  The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models , 2018, Science Advances.

[7]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[8]  R. McLendon,et al.  Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG , 2017, Molecular Cancer Research.

[9]  Arie Perry,et al.  Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations , 2016, Brain pathology.

[10]  E. Brown,et al.  DNA-PKcs, ATM and ATR interplay maintains genome integrity during neurogenesis. , 2016, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  R. McLendon,et al.  Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas , 2014, Nature Genetics.

[12]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[13]  Michael Brudno,et al.  Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations , 2014, Nature Genetics.

[14]  D. Kirsch,et al.  PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma , 2013, PloS one.

[15]  V. Kuperman,et al.  Use of radiation protraction to escalate biologically effective dose to the treatment target. , 2011, Medical physics.

[16]  Y. Shibamoto,et al.  Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor. , 2011, International journal of radiation oncology, biology, physics.

[17]  F. Alt,et al.  ATM Damage Response and XLF Repair Factor are Functionally Redundant In Joining DNA Breaks , 2010, Nature.

[18]  O. Grundmann,et al.  Sensitivity of Salivary Glands to Radiation: from Animal Models to Therapies , 2009, Journal of dental research.

[19]  E. Holland,et al.  Modeling Adult Gliomas Using RCAS/t-va Technology. , 2009, Translational oncology.

[20]  M. Kastan,et al.  Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. , 2008, Cancer research.

[21]  D A Morgan,et al.  The role of biologically effective dose (BED) in clinical oncology. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[22]  M. Kastan,et al.  The many substrates and functions of ATM , 2000, Nature Reviews Molecular Cell Biology.

[23]  P. Leder,et al.  Loss of atm radiosensitizes multiple p53 null tissues. , 1998, Cancer research.

[24]  J. Morgan,et al.  Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. , 1998, Science.

[25]  H. Withers,et al.  Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. , 1995, International journal of radiation oncology, biology, physics.

[26]  J F Fowler,et al.  The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation. , 1976, Radiation research.

[27]  Eddie Barendsen,et al.  21 years of Biologically Effective Dose , 2022 .